Insufficient enrollment

The purpose of this study is to understand the patient profile, utilized treatments, treatment patterns, resulting outcomes, and associated costs relating to luspatercept treatment in patients with lower-risk myelodysplastic syndromes (LR-MDS) or beta-thalassemia in the real-world setting

Inclusion Criteria:

• Participants treated with luspatercept. The date of first treatment with luspatercept will be assigned as the index date.
• At least one Lower-risk myelodysplastic syndromes (LR-MDS) or beta-thalassemia diagnosis in inpatient or at least two MDS or beta-thalassemia diagnosis in the outpatient setting at least 30 days apart prior to or at index date.
• 18+ years old at index date.
• Participants with a minimum of 12-months observable pre-treatment baseline/look-back prior to index date.
• Participants with a minimum of 6-months of follow-up time from the index date unless the patient is lost due to death

Exclusion Criteria:

• None

The study population will include adult patients diagnosed with myelodysplastic syndromes or beta-thalassemia and treated with luspatercept between January 1, 2020, to June 30, 2022, identified from a German Statutory Health Insurance database